Method for Detecting Coronavirus Infection
AssigneesNational University Corporation Kumamoto University, Shimadzu Corporation, AiSTI SCIENCE CO., Ltd.
InventorsKazuhito TOMIZAWA, Yu NAGAYOSHI
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a method for determining that a subject is at risk of suffering or is suffering from COVID-19. The present invention provides a method for determining whether a subject that is a mammal is at risk of suffering or suffering from COVID-19, the method including a step of detecting the amount of at least one modified nucleoside selected from the group consisting of 6-threonylcarbamoyl adenosine (t6A) and 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject.
Claims19
A method for determining a treatment policy of a subject that is a mammal based on a result of determining whether the subject is at risk of suffering or is suffering from COVID-19, the method comprising:
- a step of detecting an amount of a modified nucleoside which is 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject;
- a step of determining whether the subject is at risk of suffering or is suffering from COVID-19 based on the amount of the modified nucleoside detected;
- and
- a step of determining a treatment policy of the subject based on a result of the determination.
A method for determining a treatment policy of a subject that is a mammal suffering from COVID-19, the method comprising:
- a step of detecting an amount of a modified nucleoside which is 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from a subject;
- a step of evaluating a therapeutic effect in the subject based on the amount of the modified nucleoside detected;
- and
- a step of determining a treatment policy of the subject based on a result of the evaluation.
A method for determining a treatment policy of a subject that is a mammal based on a result of determining whether the subject is a therapeutic subject of COVID-19, the method comprising:
- a step of detecting an amount of a modified nucleoside which is 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject;
- a step of determining whether the subject is a therapeutic subject of COVID-19 based on the amount of the modified nucleoside detected;
- and
- a step of determining a treatment policy of the subject based on a result of the determination.
A method for determining a treatment policy of a subject that is a mammal suffering from COVID-19, the method comprising:
- a step of detecting an amount of a severity marker or severity predictive marker of COVID-19, made of 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A), in a sample derived from a subject;
- a step of determining severity of the subject based on the amount of the severity marker or severity predictive marker detected;
- and
- a step of determining a treatment policy of the subject based on a result of the determination.
Dependencies are inferred from the claim text.